Endometrial Cancer
DESTINY-Endometrial 01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as FirstLine Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer. (D781DC00001)
- Details
ClinicalTrials.gov ID:
NCT06989112
Diagnosis Type:
NA
USOR Number:
- Address
,
P: